Multicenter Expanded Access Protocol of ATA129 for Subjects with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
|Atara Biotherapeuticcs, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Ran Reshef, MD: 646-317-4805 / firstname.lastname@example.org
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (people who have had a transplant and those who have immune disorders), EBV can cause certain diseases where cells grow abnormally. Special immune cells, called T cells, have been made that could attack the abnormal cells. If you participate, you will receive special immune cells called EBV-Cytotoxic T Lymphocytes (EBV-CTLs), made in the laboratory starting with cells from a healthy person who is immune to EBV. Treatment for you will be selected for you from a bank of frozen EBV-CTLs, based on sharing certain human leukocyte antigens (HLAs), which the EBV-CTLs need to work. EBV-CTLs have been studied previously in 2 trials. The purpose of this study is to allow you to be treated with EBV-CTLs if you have had a transplant or immune disorder and an EBV disease and there is no other satisfactory treatment options or you do not qualify to take part in other EBV-CTL studies. Your participation will help us to understand about responses to treatment and any side effects that may occur in research subjects/participants treated with EBV-CTLs.
This study is closed
Ran Reshef, MD
|Have you been diagnosed with lymphoma?